Our data suggest that the development of depressive side effects during therapy with pegylated IFN-α and ribavirin for chronic hepatitis C is associated with a selective hyper-responsiveness of the IFN system. The gene discussed is IFNA1; the disease is chronic hepatitis C virus infection.